Thirty years of hemovigilance - Achievements and future perspectives.


Journal

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 30 09 2022
accepted: 30 09 2022
pubmed: 11 10 2022
medline: 7 2 2023
entrez: 10 10 2022
Statut: ppublish

Résumé

Since its emergence in the early 1990s, hemovigilance has gradually evolved from a blood safety concept focused on surveillance of adverse reactions and events in patients, to a well-defined system that monitors the entire transfusion chain and improves its safety. The importance of hemovigilance has been recognized globally in a relatively short time, but the level of its implementation varies significantly between countries. The cooperation of international organizations has significantly contributed to the promotion, implementation, and education in this field. Thanks to initiatives taken, the safety of transfusion practice has been improved in many segments, primarily related to the risks of adverse events in recipients of blood components. In parallel with changing transfusion practice, the hemovigilance process has also matured. In addition to the reduction of existing risks and the early detection of emerging risks, hemovigilance has also embraced the principles of patient blood management. Research in hemovigilance is more increasingly focused on specific categories of patients, specific blood components and methods of their preparation, rare reactions, and transfusion efficacy and efficiency. A proactive approach and use of big data can play an important role in achieving these goals. Additional and sustained efforts should be made to prevent underreporting of events and to improve data comparability through clear definitions and grading systems. This review provides a historical overview of hemovigilance and its achievements, current challenges, and future plans.

Identifiants

pubmed: 36216308
pii: S1246-7820(22)00313-5
doi: 10.1016/j.tracli.2022.09.070
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-172

Informations de copyright

Copyright © 2022 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Tomislav Vuk (T)

Croatian Institute of Transfusion Medicine, Zagreb, Croatia. Electronic address: tomislav.vuk@hztm.hr.

Constantina Politis (C)

Coordinating Centre for Haemovigilance and Surveillance of Transfusion, National Public Health Organization, Athens, Greece.

Stefan Laspina (S)

Department of Pathology, Mater Dei Hospital, Malta.

Miquel Lozano (M)

Department of Hemotherapy and Hemostasis, ICMHO, University Clinic Hospital, IDIBAPS, University of Barcelona, Barcelona, Spain.

Antoine Haddad (A)

Department of Clinical Pathology and Blood Bank, Sacré-Coeur Hospital, Lebanese University, Beirut, Lebanon; Lebanese American University, Beirut, Lebanon.

Vincenzo de Angelis (V)

Italian National Blood Centre, Rome, Italy.

Olivier Garraud (O)

SAINBIOSE-INSERM_U1059, Faculty of Medicine, University of Saint-Etienne, Saint-Etienne, France.
SAINBIOSE-INSERM_U1059, Faculty of Medicine, University of Saint-Etienne, Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH